advertisement
Abstract #100343 Published in IGR 23-1
High-risk Pathologic Features Based on Presenting Findings in Advanced Intraocular Retinoblastoma: A Multicenter, International Data-Sharing American Joint Committee on Cancer Study
Tomar AS; Tomar AS; Finger PT; Gallie B; Gallie B; Kivelä TT; Mallipatna A; Mallipatna A; Zhang C; Zhao J; Wilson MW; Wilson MW; Brennan RC; Brennan RC; Burges M; Burges M; Kim J; Berry JL; Berry JL; Jubran R; Jubran R; Khetan V; Ganesan S; Ganesan S; Yarovoy A; Yarovoy A; Yarovaya V; Yarovaya V; Kotova E; Kotova E; Volodin D; Volodin D; Yousef YA; Nummi K; Nummi K; Ushakova TL; Ushakova TL; Yugay OV; Yugay OV; Polyakov VG; Polyakov VG; Ramirez-Ortiz MA; Ramirez-Ortiz MA; Esparza-Aguiar E; Esparza-Aguiar E; Chantada G; Chantada G; Schaiquevich P; Schaiquevich P; Fandino A; Yam JC; Lau WW; Lau WW; Lam CP; Lam CP; Sharwood P; Sharwood P; Moorthy S; Moorthy S; Long QB; Long QB; Essuman VA; Renner LA; Renner LA; Semenova E; Català-Mora J; Català-Mora J; Correa-Llano G; Correa-Llano G; Carreras E;Ophthalmology 2022; 129: 923-932
PURPOSE: To determine the value of clinical features for advanced intraocular retinoblastoma as defined by the eighth edition of the American Joint Committee on Cancer (AJCC) cT3 category and AJCC Ophthalmic Oncology Task Force (OOTF) Size Groups to predict the high-risk pathologic features. DESIGN: International, multicenter, registry-based retrospective case series. PARTICIPANTS: Eighteen ophthalmic oncology centers from 13 countries over 6 continents shared evaluations of 942 eyes enucleated as primary treatment for AJCC cT3 and, for comparison, cT2 retinoblastoma. METHODS: International, multicenter, registry-based data were pooled from patients enrolled between 2001 and 2013. High-risk pathologic features were defined as AJCC categories pT3 and pT4. In addition, AJCC OOTF Size Groups were defined as follows: (1) less than half, (2) more than half but less than two thirds, (3) more than two thirds of globe volume involved, and (4) diffuse infiltrating retinoblastoma. MAIN OUTCOME MEASURES: Statistical risk of high-risk pathologic features corresponding to AJCC cT3 subcategories and AJCC OOTF Size Groups. RESULTS: Of 942 retinoblastoma eyes treated by primary enucleation, 282 (30%) showed high-risk pathologic features. Both cT subcategories and AJCC OOTF Size Groups (P < 0.001 for both) were associated with high-risk pathologic features. On logistic regression analysis, cT3c (iris neovascularization with glaucoma), cT3d (intraocular hemorrhage), and cT3e (aseptic orbital cellulitis) were predictive factors for high-risk pathologic features when compared with cT2a with an odds ratio of 2.3 (P = 0.002), 2.5 (P = 0.002), and 3.3 (P = 0.019), respectively. Size Group 3 (more than two-thirds globe volume) and 4 (diffuse infiltrative retinoblastoma) were the best predictive factors with an odds ratio of 3.3 and 4.1 (P < 0.001 for both), respectively, for high-risk pathologic features when compared with Size Groups 1 (i.e., < 50% of globe volume). CONCLUSIONS: The AJCC retinoblastoma staging clinical cT3c-e subcategories (glaucoma, intraocular hemorrhage, and aseptic orbital cellulitis, respectively) as well as the AJCC OOTF Size Groups 3 (tumor more than two thirds of globe volume) and 4 (diffuse infiltrative retinoblastoma) both allowed stratification of clinical risk factors that can be used to predict the presence of high-risk pathologic features and thus facilitate treatment decisions.
Department of Ocular Tumor and Orbital Disease, The New York Eye Cancer Center, New York, New York.
Full article